CYTADREN Drug Patent Profile
✉ Email this page to a colleague
When do Cytadren patents expire, and when can generic versions of Cytadren launch?
Cytadren is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in CYTADREN is aminoglutethimide. Additional details are available on the aminoglutethimide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CYTADREN?
- What are the global sales for CYTADREN?
- What is Average Wholesale Price for CYTADREN?
Summary for CYTADREN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 111 |
Clinical Trials: | 1 |
Patent Applications: | 4,397 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CYTADREN at DailyMed |
![CYTADREN drug patent expirations Drug patent expirations by year for CYTADREN](/p/graph/s/t/CYTADREN-patent-expirations.png)
Recent Clinical Trials for CYTADREN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Janssen Pharmaceuticals | Phase 2 |
H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for CYTADREN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | CYTADREN | aminoglutethimide | TABLET;ORAL | 018202-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CYTADREN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | CYTADREN | aminoglutethimide | TABLET;ORAL | 018202-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | CYTADREN | aminoglutethimide | TABLET;ORAL | 018202-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |